
Supplemental Figure S1



Supplemental Figure S1.

Additional protein/mRNA expression data (corresponding to Figure 2). A, Western blots for pγH2AX in PSaRC318, A673, and CHLA10 Ewing sarcoma cells under the treatment conditions noted. These data correspond to the immunofluorescence data for pγH2AX in Figure 2B. **B**, A673 Ewing sarcoma cells were transfected with SMART pool control (non-targeting) siRNA (ctsi), SMART pool BARDsiRNA, or one of four individual BARD1siRNAs from the pool (#1-#4) for 72 hours. Resulting RNA(cDNA) was subjected to RT-PCR analysis for *BARD1*. **C**, Western blot for BARD1 expression in CHLA10 cells treated with DMSO, Talazoparib (Tal), doxorubicin (20nM) or untreated. Values under western blots in **A** and **C** represent relative expression as determined by densitometry analysis. Experiments were performed minimally in biological triplicate. *** denotes p< 0.0001, error bars denote S.D.